Advertisement
Screener

BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

BLACK DIAMOND THERAPEUTICS, INC. Capital Expenditures

BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Capital Expenditures of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-06

  • BLACK DIAMOND THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00.
  • BLACK DIAMOND THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $0.00.
  • BLACK DIAMOND THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $33.00K.
  • BLACK DIAMOND THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
  • BLACK DIAMOND THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
  • BLACK DIAMOND THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $33.00K, a 82.81% decline from fiscal 2022.
  • BLACK DIAMOND THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $192.00K, a 92.92% decline from fiscal 2021.
  • BLACK DIAMOND THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $2.71M, a 1808.45% increase from fiscal 2020.
Period endPayments to Acquire Property, Plant, and Equipment 3 monthPayments to Acquire Property, Plant, and Equipment 6 monthPayments to Acquire Property, Plant, and Equipment 9 monthPayments to Acquire Property, Plant, and Equipment 12 month
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
$0.00
10-K · filed 2025-03-06
2024-09-30$0.00
10-Q · filed 2024-11-05
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
$33.00K
derived: sum of 2 quarters · filed 2025-03-06
$33.00K
derived: sum of 3 quarters · filed 2025-03-06
$33.00K
10-K · filed 2025-03-06
2023-09-30$33.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05
$33.00K
derived: sum of 2 quarters · filed 2024-11-05
$33.00K
10-Q · filed 2024-11-05
$33.00K
derived: sum of 4 quarters · filed 2024-11-05
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
$0.00
10-Q · filed 2023-08-11
$0.00
derived: sum of 3 quarters · filed 2024-03-12
-$8.00K
derived: sum of 4 quarters · filed 2024-03-12
2023-03-31$0.00
10-Q · filed 2023-05-09
$0.00
derived: sum of 2 quarters · filed 2024-03-12
-$8.00K
derived: sum of 3 quarters · filed 2024-03-12
$185.00K
derived: sum of 4 quarters · filed 2024-03-12
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
-$8.00K
derived: sum of 2 quarters · filed 2024-03-12
$185.00K
derived: sum of 3 quarters · filed 2024-03-12
$192.00K
10-K · filed 2024-03-12
2022-09-30-$8.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
$185.00K
derived: sum of 2 quarters · filed 2023-11-06
$192.00K
10-Q · filed 2023-11-06
$525.00K
derived: sum of 4 quarters · filed 2023-11-06
2022-06-30$193.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
$200.00K
10-Q · filed 2023-08-11
$533.00K
derived: sum of 3 quarters · filed 2023-08-11
$2.02M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31$7.00K
10-Q · filed 2023-05-09
$340.00K
derived: sum of 2 quarters · filed 2023-05-09
$1.83M
derived: sum of 3 quarters · filed 2023-05-09
$2.68M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$333.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
$1.82M
derived: sum of 2 quarters · filed 2023-03-09
$2.67M
derived: sum of 3 quarters · filed 2023-03-09
$2.71M
10-K · filed 2023-03-09
2021-09-30$1.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$2.34M
derived: sum of 2 quarters · filed 2022-11-08
$2.38M
10-Q · filed 2022-11-08
$2.49M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$848.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$888.00K
10-Q · filed 2022-08-09
$997.00K
derived: sum of 3 quarters · filed 2022-08-09
$1.00M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$40.00K
10-Q · filed 2022-05-11
$149.00K
derived: sum of 2 quarters · filed 2022-05-11
$157.00K
derived: sum of 3 quarters · filed 2022-05-11
$182.00K
derived: sum of 4 quarters · filed 2022-05-11
2020-12-31$109.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
$117.00K
derived: sum of 2 quarters · filed 2022-03-17
$142.00K
derived: sum of 3 quarters · filed 2022-03-17
$142.00K
10-K · filed 2022-03-17
2020-09-30$8.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$33.00K
derived: sum of 2 quarters · filed 2021-11-08
$33.00K
10-Q · filed 2021-11-08
$35.00K
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30$25.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$25.00K
10-Q · filed 2021-08-12
$27.00K
derived: sum of 3 quarters · filed 2021-08-12
$38.00K
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$0.00
10-Q · filed 2021-05-07
$2.00K
derived: sum of 2 quarters · filed 2021-05-07
$13.00K
derived: sum of 3 quarters · filed 2021-05-07
$11.00K
derived: sum of 4 quarters · filed 2021-05-07
2019-12-31$2.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
$13.00K
derived: sum of 2 quarters · filed 2021-03-25
$11.00K
derived: sum of 3 quarters · filed 2021-03-25
$21.00K
10-K · filed 2021-03-25
2019-09-30$11.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
$9.00K
derived: sum of 2 quarters · filed 2020-11-10
$19.00K
10-Q · filed 2020-11-10
2019-06-30-$2.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11
$8.00K
10-Q · filed 2020-08-11
2019-03-31$10.00K
10-Q · filed 2020-05-12
2018-12-31$76.00K
10-K · filed 2020-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Vaxart, Inc. (VXRT)United States$0.080B3.84